Wakayama Kenji, Kamiyama Toshiya, Yokoo Hideki, Orimo Tatsuya, Shimada Shingo, Einama Takahiro, Kamachi Hirofumi, Taketomi Akinobu
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan.
J Surg Oncol. 2017 Mar;115(3):324-329. doi: 10.1002/jso.24501. Epub 2017 Feb 13.
This study aimed to evaluate the impact of huge (≥10 cm) hepatocellular carcinoma (HCC) to the recurrence pattern and the prognosis after hepatectomy.
574 patients who underwent hepatectomy by 17 surgeons (Open 536 and Laparoscopic 38) for HCC without major vascular invasion from 1990 to 2013 at single institute were retrospectively analyzed.
Huge tumor, age, HCV, multiple tumors and microscopic portal invasion are independent risk factors for overall survival (OS), and huge tumor, ICGR15 ≥16%, multiple tumors, moderate/poor histology, microscopic portal invasion and a positive pathological margin are risk factors for relapse-free survival (RFS). The 5-year OS and RFS of patients with huge HCC (n = 53) (42.9 and 14.2%) were significantly worse than those of patients with HCC <10 cm (n = 521) (71.3 and 33.1%). Huge tumor is an independent risk factor for initial extra-hepatic recurrence (Hazard ratio 7.86, P < 0.0001). The 5-year OS of patients with initial extra-hepatic recurrence (n = 55) was significantly worse than patients with intra-hepatic recurrence (n = 338) (16.8 vs. 50.5%).
Huge HCC (≥10 cm) is an independent risk factor due to a high risk for initial extra-hepatic recurrence. Future systemic adjuvant therapy is needed for these patients. J. Surg. Oncol. 2017;115:324-329. © 2016 Wiley Periodicals, Inc.
本研究旨在评估巨大(≥10 cm)肝细胞癌(HCC)对肝切除术后复发模式及预后的影响。
回顾性分析了1990年至2013年期间在单中心由17名外科医生进行肝切除术(开放手术536例,腹腔镜手术38例)治疗的574例无主要血管侵犯的HCC患者。
巨大肿瘤、年龄、丙型肝炎病毒(HCV)感染、多肿瘤及镜下门静脉侵犯是总生存期(OS)的独立危险因素,而巨大肿瘤、吲哚氰绿15分钟潴留率(ICGR15)≥16%、多肿瘤、组织学分级中/差、镜下门静脉侵犯及病理切缘阳性是无复发生存期(RFS)的危险因素。巨大HCC患者(n = 53)的5年OS和RFS(分别为42.9%和14.2%)显著低于肿瘤<10 cm的HCC患者(n = 521)(分别为71.3%和33.1%)。巨大肿瘤是初始肝外复发的独立危险因素(风险比7.86,P < 0.0001)。初始肝外复发患者(n = 55) 的5年OS显著低于肝内复发患者(n = 338)(16.8%对50.5%)。
巨大HCC(≥10 cm)因初始肝外复发风险高而成为独立危险因素。这些患者未来需要全身辅助治疗。《外科肿瘤学杂志》2017年;115:324 - 329。© 2016威利期刊公司